MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus.

Trial Profile

MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Nov 2008 Actual end date (1 Feb 2008 to May 2008) changed, as reported by ClinicalTrials.gov.
    • 23 Sep 2008 Results have been reported at EASD 2008 (44th Annual Meeting of the European Association for the Study of Diabetes).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top